Statistics from Altmetric.com
In 2000, the European Union (EU) legislated to encourage the pharmaceutical industry to develop ‘orphan’ drugs (i.e. drugs for rare diseases).1 Incentives include up to 10-year market exclusivity, licensing fee reductions, and initiatives supporting research and development.1 Without incentives, such drugs would be unlikely to attract industry investment. However, sometimes there has been a high resulting price …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.